Innoviva (NASDAQ:INVA) Now Covered by Analysts at Oppenheimer
Stock analysts at Oppenheimer began coverage on shares of Innoviva (NASDAQ:INVA – Get Free Report) in a research report issued to clients and investors on Monday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $45.00 price target on the biotechnology company’s stock. Oppenheimer’s price objective would indicate a potential upside of 123.99% […]
More Stories
Is Imperfect Women Season 2 Renewed?
Apple TV just dropped the most-awaited news for psychological thriller fans. Imperfect Women season 2 is happening. If you watched...
What Makes Live Dealer Casino Games Feel Like the Real Table?
There is a noticeable difference between watching an animated roulette wheel and seeing a real ball circle a physical wheel....
How to Match Native Display Ads to Your Content and Campaign Goals
A native campaign can struggle when the ad attracts one kind of interest but the destination asks for something different....
491 Fugitives Hiding in Public Housing Arrested in Nationwide Sweep
By Naveen Athrappully A multi-month law enforcement operation has led to the arrests of 491 criminal fugitives living in government-assisted...
Trump Doubles Down on $5,000 Payments Tied to Midterm Results
By Jack Phillips President Donald Trump on Monday released a new advertisement that doubled down on his promise to send...
Zelenskyy Says Strikes on Russian Refineries Will Continue If Putin Rejects Energy Ceasefire
By Owen Evans Ukraine will continue its long-range strikes against Russia if Moscow doesn’t accept an energy truce, President Volodymyr...